Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Avalon GloboCare Announces $6 Million Registered Direct Offering with Institutional Investors
BiotechnologyCompany Update

Avalon GloboCare Announces $6 Million Registered Direct Offering with Institutional Investors

April 25, 2019 8:58 AM

FREEHOLD, NJ / ACCESSWIRE / April 25, 2019 / Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has entered into a purchase agreement with several institutional investors for the purchase of 1,714,288 units in a registered direct offering, for expected gross proceeds of approximately $6 million before placement agent fees and other offering expenses payable by the...

Read more
Oncolytics Biotech(R) Announces Details of 2019  Annual General Meeting of Shareholders
BiotechnologyConference Call

Oncolytics Biotech(R) Announces Details of 2019 Annual General Meeting of Shareholders

April 25, 2019 7:00 AM

CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 25, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that its Annual General Meeting of Shareholders will be held on Thursday, May 2nd, 2019 at 4:00 pm ET at Vantage Venues (formerly St. Andrew's Club & Conference Center) located at 150 King St. West, 27th Floor, Toronto,...

Read more
Pressure BioSciences, Inc. to Discuss Fourth Quarter and Fiscal Year 2018 Financial Results and Provide Business Update
BiotechnologyEarnings

Pressure BioSciences, Inc. to Discuss Fourth Quarter and Fiscal Year 2018 Financial Results and Provide Business Update

April 24, 2019 9:52 AM

Conference Call Scheduled for Thursday, April 25th at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / April 24, 2019 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Fourth Quarter and Fiscal Year 2018 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by...

Read more
Eminent M.I.T. Institute Professor, Robert S. Langer, Sc.D., Joins Avalon GloboCare's Scientific and Clinical Advisory Board
BiotechnologyCompany Update

Eminent M.I.T. Institute Professor, Robert S. Langer, Sc.D., Joins Avalon GloboCare's Scientific and Clinical Advisory Board

April 24, 2019 8:00 AM

MIT's David H. Koch Institute Professor; world-renowned scientist and bio-entrepreneur Anticipating collaborative projects with Avalon FREEHOLD, NJ / ACCESSWIRE / April 24, 2019 / Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that the Company has appointed Robert S. Langer, Sc.D., to its Scientific and Clinical Advisory Board. Dr. Robert S. Langer is...

Read more
Oncolytics Biotech(R) to Present at the 2019 Bloom Burton & Co.  Healthcare Investor Conference
BiotechnologyCompany Update

Oncolytics Biotech(R) to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

April 23, 2019 7:00 AM

CALGARY, AB and SAN DIEGO, CA / ACCESSWIRE / April 23, 2019 / Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that it would present at the 2019 Bloom Burton & Co. Investor Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 11:00 am ET, on Tuesday, April 30, 2019, at the Metro Toronto Convention...

Read more
Uni-Bio Group (HK690)'s Uni-PTH (Teriparatide) High-Precision Industrialization Project Was Successfully Approved Focus on the Transformation of Major Frontier Achievements Targeting the Tens of Billions Osteoporosis Market
BiotechnologyCompany Update

Uni-Bio Group (HK690)'s Uni-PTH (Teriparatide) High-Precision Industrialization Project Was Successfully Approved Focus on the Transformation of Major Frontier Achievements Targeting the Tens of Billions Osteoporosis Market

April 18, 2019 9:25 AM

Uni-Bio Group (HK690)'s Uni-PTH (Teriparatide) High-Precision Industrialization Project Was Successfully Approved Focus on the Transformation of Major Frontier Achievements Targeting the Tens of Billions Osteoporosis Market HONG KONG / ACCESSWIRE / April 18, 2019 / A fully integrated biopharmaceutical company - Uni-Bio Science Group Limited ("Uni-Bio Science", together with its subsidiaries, referred to as the "Group"; Stock code: 0690.HK), is...

Read more
Avalon GloboCare to Host The 3rd Annual International Scientific Forum on Exosome Research and Application (ISFERA) in Beijing on July 19, 2019
BiotechnologyCompany Update

Avalon GloboCare to Host The 3rd Annual International Scientific Forum on Exosome Research and Application (ISFERA) in Beijing on July 19, 2019

April 17, 2019 8:00 AM

Co-organized with the Regenerative Medicine Foundation Concurrent with the 7th Annual Lu Daopei Hematology Forum FREEHOLD, NJ / ACCESSWIRE / April 17, 2019 / Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative and transformative cell-based technologies and therapeutics, announced today that it will co-organize the 3rd Annual International Scientific Forum on Exosome Research and Application (ISFERA) with...

Read more
Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year for 2018
BiotechnologyEarnings

Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year for 2018

April 15, 2019 9:00 AM

PLAINVIEW, NY / ACCESSWIRE / April 15, 2019 / Vaso Corporation ("Vaso") (OTC PINK: VASO) today reported its operating results for the three months and year ended December 31, 2018. "The Company's total revenue continued to increase, to $74.0 million, for the fiscal year 2018, thanks to the growth in our IT segment and proprietary medical equipment segment, at 3.9% and 12.7%, respectively," stated Dr. Jun Ma, President and Chief Executive Officer...

Read more
Dyadic Announces Uplisting to the Nasdaq Capital Market
BiotechnologyCompany Update

Dyadic Announces Uplisting to the Nasdaq Capital Market

April 15, 2019 8:00 AM

JUPITER, FL / ACCESSWIRE / April 15, 2019 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, is pleased to announce that its common stock has been approved to list on The Nasdaq Capital...

Read more
Lexaria Bioscience Engages Oak Hill Financial Inc. to Provide Investor Relations Services
BiotechnologyInvestor Relations

Lexaria Bioscience Engages Oak Hill Financial Inc. to Provide Investor Relations Services

April 15, 2019 6:00 AM

KELOWNA, BC / ACCESSWIRE / April 15, 2019 / Lexaria Bioscience Corp. (CNSX: LXX) (OTCQB: LXRP) ("Lexaria" or the "Company") announces it has retained Oak Hill Financial Inc. ("Oak Hill") to provide investor relations services to the Company in compliance with regulatory guidelines. Oak Hill is a Toronto-based firm that develops strategic platforms for its clients that are utilized to gain exposure and recognition in the capital markets. Oak...

Read more
HemaGenetics Announces Setting of the Effective Date for the Plan of Arrangement with 1169032 B.C. Ltd.
BiotechnologyCompany Update

HemaGenetics Announces Setting of the Effective Date for the Plan of Arrangement with 1169032 B.C. Ltd.

April 11, 2019 7:30 PM

VANCOUVER, BC / ACCESSWIRE / April 11, 2019 / HemaGenetics Technologies Corp. (the 'Company') is pleased to announce that further to the previously announced arrangement under the arrangement agreement entered into on June 26, 2018 between the Company, Mucho Cobre Resources Ltd. (formerly, 1169080 B.C. Ltd.), 1169029 B.C. Ltd., 1169032 B.C. Ltd., 1169071 B.C. Ltd., 1169077 B.C. Ltd., and 1169082 B.C. Ltd. (the 'Arrangement'), the...

Read more
Hancock Jaffe Successfully Completes Four VenoValve Implantations for First-in-Human Study
BiotechnologyCompany Update

Hancock Jaffe Successfully Completes Four VenoValve Implantations for First-in-Human Study

April 11, 2019 8:31 AM

Five Patients Now Part of First-in-Human Bogota Study IRVINE, CA / ACCESSWIRE / April 11, 2019 / Hancock Jaffe Laboratories, Inc. (NASDAQ: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, has successfully implanted VenoValves in four additional patients for its first-in-human study in Bogota, Colombia. The surgeries went well and there are no early signs of adverse events. HJLI previously announced that the...

Read more
EastWest Comments on 2Q Financial Statements and Expands on Vision, Strategy, and Execution
BiotechnologyEarnings

EastWest Comments on 2Q Financial Statements and Expands on Vision, Strategy, and Execution

April 8, 2019 9:00 AM

VANCOUVER, BC / ACCESSWIRE / April 8, 2019 / EastWest Bioscience (the "Company" or "EastWest") (TSX.V: EAST) expands on its vision, strategy, and outlook for the future and comments on its 2Q financial results for the three months ended January 31, 2019. "It has been a very busy operational quarter," explains Rodney Gelineau, CEO of Eastwest BioScience. "The team has been tasked with integration of the Sangster's purchase, as well as...

Read more
Avalon GloboCare Appoints Finance Veteran Yue ''Charles'' Li to the Board of Directors
BiotechnologyCompany Update

Avalon GloboCare Appoints Finance Veteran Yue ''Charles'' Li to the Board of Directors

April 8, 2019 8:35 AM

Reappoints Meng Li to Board of Directors FREEHOLD, NJ / ACCESSWIRE / April 8, 2019 / Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative and transformative cell-based technologies and therapeutics, announced today the addition of Yue "Charles" Li to the Company's Board of Directors. Mr. Li qualifies as an independent director and will serve on the acquisition task force committee. The Company also announced the...

Read more
Zivo Commences Third Dairy Cow Mastitis Trial to Validate Efficacy and Method of Administration for a New Pathogen Target
BiotechnologyCompany Update

Zivo Commences Third Dairy Cow Mastitis Trial to Validate Efficacy and Method of Administration for a New Pathogen Target

April 8, 2019 8:00 AM

KEEGO HARBOR, MI / ACCESSWIRE / April 8, 2019 / ZIVO Bioscience, Inc. (OTCQB: ZIVO) a Michigan-based biotech/agtech R&D company has commenced a third in vivo dairy cow mastitis study to validate its bioactive compounds in combating a specific infective pathogen via a specific method of administration. Neither the pathogen nor the method of administration can be disclosed at this time, other than to characterize the pathogen as a widespread...

Read more
AYOXXA Biosystems GmbH: AYOXXA launches LUNARIS(TM) Human and Mouse Chemokine Kits to explore chemokine signaling
BiotechnologyProduct Announcements

AYOXXA Biosystems GmbH: AYOXXA launches LUNARIS(TM) Human and Mouse Chemokine Kits to explore chemokine signaling

April 8, 2019 5:25 AM

AYOXXA launches LUNARISTM Human and Mouse Chemokine Kits to explore chemokine signaling LUNARISTM Chemokine Kits are validated for the quantitative analysis of up to 12 different chemokines in one sample Panel composition is harmonized across species to allow translation of results from murine and human samples - from lab to clinic The LUNARISTM platform enables robust and scalable profiling of homeostatic and proinflammatory...

Read more
Brighthaven Ventures LLC Announces Dismissal of Lawsuit on Motion For Summary Judgement
BiotechnologyCompany UpdateLawsuits

Brighthaven Ventures LLC Announces Dismissal of Lawsuit on Motion For Summary Judgement

April 5, 2019 8:45 AM

RESEARCH TRIANGLE PARK, NC / ACCESSWIRE / April 5, 2019 / Brighthaven Ventures LLC. ("BHV"), a wholly owned subsidiary of Avolynt, Inc., a company focused on the development of therapeutics for rare and metabolic diseases, announced today the dismissal of civil litigation against BHV executives in the United States District Court, Southern District of New York. In 2015, Richard Schoninger, Scott Schoninger, Jacqueline Schoninger, Gerald Allen,...

Read more
EBD Group: Vienna Welcomed 2,570 Life Science Executives for Partnering Success at BIO-Europe Spring(R) 2019
BiotechnologyConferencesConference Call

EBD Group: Vienna Welcomed 2,570 Life Science Executives for Partnering Success at BIO-Europe Spring(R) 2019

April 5, 2019 7:40 AM

ZUG, SWITZERLAND and VIENNA, AUSTRIA / ACCESSWIRE / April 5, 2019 / The highly successful thirteenth annual BIO-Europe Spring(R) international partnering conference wrapped up in Vienna, Austria, last week with a record 2,570 biotech, pharma and investment attendees who engaged in 15,428 one-to-one partnering meetings vying for over 3,600 licensing opportunities on offer. The event welcomed 1,465 companies overall. BIO-Europe Spring was produced...

Read more
HemaGenetics Technologies Announces Acquisition of HemaGenetic Research Group
BiotechnologyCompany UpdateMergers and Acquisitions

HemaGenetics Technologies Announces Acquisition of HemaGenetic Research Group

April 4, 2019 3:20 PM

VANCOUVER, BC / ACCESSWIRE / April 4, 2019 / HemaGenetics Technologies Corp. (the "Company" or "HemaGenetics") announces that it has signed a Share Purchase and Sale Agreement (the "SPSA") to acquire the HemaGenetic Research Group ("HRG") owned and operated by Dr. Haixing Chen. The Company anticipates closing on the SPSA on or before Friday, April 12, 2019. About HRG HRG is a private research group that has developed patented gene technology for...

Read more
Pieris Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
BiotechnologyCompany Update

Pieris Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

April 3, 2019 8:50 AM

BOSTON, MA / ACCESSWIRE / April 3, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer and other diseases, announced today that Allan Reine, Senior Vice President and Chief Financial Officer of Pieris Pharmaceuticals, Inc. will present at the 2019 H.C. Wainwright Global Life Sciences Conference in...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?